ALKS - Alkermes PLC Stock Price, Fair Value and News

24.08USD+0.22 (+0.92%)Market Closed

Market Summary

USD24.08+0.22

Market Closed

0.92%

ALKS Alerts

Big jump in Earnings (Y/Y)

ALKS Stock Price

View Fullscreen

ALKS RSI Chart

ALKS Valuation

Market Cap

4.1B

Price/Earnings (Trailing)

9.38

Price/Sales (Trailing)

2.36

EV/EBITDA

6.52

Price/Free Cashflow

10.34

ALKS Price/Sales (Trailing)

ALKS Profitability

EBT Margin

29.91%

Return on Equity

34.62%

Return on Assets

20.45%

Free Cashflow Yield

9.67%

ALKS Fundamentals

ALKS Revenue

Revenue (TTM)

1.7B

Rev. Growth (Yr)

21.83%

Rev. Growth (Qtr)

-7.18%

ALKS Earnings

Earnings (TTM)

434.4M

Earnings Growth (Yr)

188.01%

Earnings Growth (Qtr)

-67.34%

Breaking Down ALKS Revenue

Last 7 days

-2.4%

Last 30 days

-8.5%

Last 90 days

-10.0%

Trailing 12 Months

-16.1%

How does ALKS drawdown profile look like?

ALKS Financial Health

Current Ratio

3.2

Debt/Equity

0.23

Debt/Cashflow

1.55

ALKS Investor Care

Shares Dilution (1Y)

1.87%

Diluted EPS (TTM)

2.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.7B	0	0	0
2023	1.1B	1.5B	1.6B	1.7B
2022	1.2B	1.2B	1.1B	1.1B
2021	1.0B	1.1B	1.1B	1.2B
2020	1.2B	1.2B	1.2B	1.0B
2019	1.1B	1.1B	1.1B	1.2B
2018	936.7M	1.0B	1.1B	1.1B
2017	780.7M	804.4M	841.5M	903.4M
2016	623.9M	667.7M	695.3M	745.7M
2015	649.8M	647.7M	640.4M	628.3M
2014	563.1M	577.9M	598.1M	618.8M
2013	575.5M	561.9M	577.8M	596.3M
2012	390.0M	480.3M	532.3M	542.6M
2011	186.6M	219.3M	242.1M	331.8M
2010	178.3M	0	181.1M	183.9M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Alkermes PLC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	nichols christian todd	sold	-292,740	28.1021	-10,417	svp, chief commercial officer
Feb 27, 2024	parisi samuel joseph	sold	-75,874	29.65	-2,559	vp, finance (interim pao)
Feb 23, 2024	brown iain michael	acquired	-	-	5,825	svp, chief financial officer
Feb 23, 2024	parisi samuel joseph	acquired	-	-	2,283	vp, finance (interim pao)
Feb 23, 2024	gaffin david joseph	acquired	-	-	7,689	evp, clo, alkermes, inc.
Feb 23, 2024	jackson blair curtis	sold (taxes)	-114,732	29.57	-3,880	evp, chief operating officer
Feb 23, 2024	landine michael j	acquired	-	-	4,077	svp, corp dev., alkermes, inc.
Feb 23, 2024	nichols christian todd	sold (taxes)	-84,126	29.57	-2,845	svp, chief commercial officer
Feb 23, 2024	jackson blair curtis	acquired	-	-	8,737	evp, chief operating officer
Feb 23, 2024	brown iain michael	sold (taxes)	-76,497	29.57	-2,587	svp, chief financial officer

Which funds bought or sold ALKS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 02, 2024	NISA INVESTMENT ADVISORS, LLC	added	0.89	-38,114	2,424,230	0.02%
May 02, 2024	Quent Capital, LLC	unchanged	-	-369	14,943	-%
May 02, 2024	WHITTIER TRUST CO	unchanged	-	-278	11,229	-%
May 02, 2024	Daiwa Securities Group Inc.	added	380	180,000	229,000	-%
May 02, 2024	MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC	reduced	-6.07	-277,426	3,050,710	0.03%
May 02, 2024	JENNISON ASSOCIATES LLC	added	24.87	220,260	1,228,190	-%
May 02, 2024	State of New Jersey Common Pension Fund D	reduced	-9.08	-332,368	2,615,400	0.01%
May 01, 2024	Mirae Asset Global Investments Co., Ltd.	reduced	-6.69	-211,045	2,322,530	-%
May 01, 2024	Parkside Financial Bank & Trust	unchanged	-	-23.00	921	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	reduced	-6.13	-568,367	6,199,110	-%

Are Funds Buying or Selling ALKS?

Are funds buying ALKS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALKS

No. of Funds

ALKS Alerts

Big jump in Earnings (Y/Y)

Unveiling Alkermes PLC's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	12.56%	20,955,454	SC 13G/A
Feb 08, 2024	wellington management group llp	9.13%	15,241,470	SC 13G
Jan 24, 2024	state street corp	5.60%	9,352,970	SC 13G
Jan 08, 2024	blackrock inc.	18.0%	30,021,312	SC 13G/A
Aug 24, 2023	sarissa capital management lp	997%	8,323,400	SC 13D/A
Jun 28, 2023	sarissa capital management lp	-	0	SC 13D/A
Jun 27, 2023	sarissa capital management lp	-	0	SC 13D/A
Jun 23, 2023	sarissa capital management lp	-	0	SC 13D/A
Jun 21, 2023	sarissa capital management lp	-	0	SC 13D/A
Jun 16, 2023	sarissa capital management lp	-	0	SC 13D/A

Recent SEC filings of Alkermes PLC

View All Filings

Date Filed	Form Type	Document
May 01, 2024	10-Q	Quarterly Report
May 01, 2024	8-K	Current Report
Apr 15, 2024	ARS	ARS
Apr 15, 2024	DEF 14A	DEF 14A
Apr 15, 2024	DEFA14A	DEFA14A
Apr 12, 2024	4	Insider Trading
Apr 09, 2024	8-K	Current Report
Apr 05, 2024	PRE 14A	PRE 14A
Mar 18, 2024	144	Notice of Insider Sale Intent
Mar 18, 2024	4	Insider Trading

Peers (Alternatives to Alkermes PLC)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	359.2B	85.6B	-3.24%	-7.94%	9.34	4.19	5.68%	202.39%
MRK	323.0B	61.4B	-1.84%	8.64%	140.05	5.26	6.11%	-82.30%
AMGN	166.9B	29.5B	13.40%	34.20%	44.36	5.65	12.76%	-52.47%
PFE	157.1B	46.5B	2.20%	-27.23%	-113.14	3.37	42.59%	-114.62%
GILD	80.7B	27.1B	-8.62%	-17.50%	14.25	2.98	-0.60%	23.36%
TEVA	15.6B	15.8B	-0.99%	61.25%	-27.18	0.99	6.17%	76.47%
MID-CAP
PRGO	4.4B	4.7B	5.70%	-11.21%	-349.99	0.95	4.58%	90.97%
ALKS	4.1B	1.7B	-8.55%	-16.13%	9.38	2.36	54.01%	364.56%
BHC	2.9B	9.0B	-22.11%	32.77%	-6.3	0.32	10.01%	-27.45%
AMPH	2.0B	644.4M	1.22%	16.11%	14.84	3.17	29.14%	50.51%
SMALL-CAP
TLRY	1.6B	743.2M	-26.67%	-17.06%	-4.6	2.18	24.65%	80.36%
TXMD	22.0M	1.3M	-14.35%	-52.84%	-2.14	16.92	-98.14%	-109.18%
ACRX	17.1M	-	-	62.93%	-0.93	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	35.71%	-93.63%	-0.17	0.13	80.00%	43.08%
ACOR	1.1M	117.6M	-94.70%	-92.62%	0	0.01	-0.79%	-283.60%

Alkermes PLC News

Latest updates

Alkermes PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-7.2%	350	377	381	617	288	305	252	276	279	324	294	304	251	280	265	248	246	413	255	280	223
Costs and Expenses	54.4%	307	199	337	378	335	189	313	311	305	195	314	299	268	311	276	281	284	423	309	316	299
S&GA Expenses	27.9%	180	141	169	205	174	143	153	150	145	149	136	139	125	146	128	132	133	154	149	155	141
R&D Expenses	425.7%	68.00	-20.76	97.00	101	94.00	-16.55	100	93.00	96.00	-17.23	118	97.00	92.00	112	95.00	94.00	93.00	198	108	104	103
EBITDA Margin	12.1%	0.35*	0.31*	0.28*	0.23*	0.05*	0.05*	0.06*	0.09*	0.12*	0.15*	0.01*	0.03*	-	-	-	-	-	-	-	-	-
Interest Expenses	-1.3%	6.00	6.00	6.00	6.00	5.00	5.00	4.00	2.00	2.00	2.00	2.00	2.00	4.00	2.00	2.00	2.00	3.00	3.00	3.00	4.00	4.00
Income Taxes	108.5%	8.00	-93.93	-0.40	3.00	-6.01	18.00	-3.39	-3.11	-9.10	2.00	2.00	3.00	4.00	1.00	2.00	4.00	7.00	3.00	-0.98	2.00	-3.85
Earnings Before Taxes	-74.3%	47.00	182	47.00	240	-47.85	114	-67.37	-33.25	-45.00	127	-26.53	6.00	-18.65	-41.65	2.00	-25.76	-31.32	-2.56	-53.86	-40.39	-100
EBT Margin	18.0%	0.30*	0.25*	0.22*	0.16*	-0.03*	-0.03*	-0.02*	0.02*	0.05*	0.07*	-0.07*	-0.05*	-	-	-	-	-	-	-	-	-
Net Income	-67.3%	37.00	113	48.00	237	-41.84	-28.25	-63.97	-30.14	-35.90	1.00	-28.99	2.00	-22.42	-42.64	-0.13	-29.43	-38.65	-5.35	-52.88	-41.99	-96.40
Net Income Margin	17.7%	0.25*	0.21*	0.13*	0.07*	-0.15*	-0.14*	-0.11*	-0.08*	-0.05*	-0.04*	-0.08*	-0.06*	-	-	-	-	-	-	-	-	-
Free Cashflow	-85.8%	13.00	90.00	85.00	206	-28.16	-8.98	-9.85	-12.27	14.00	22.00	78.00	27.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.6%	2,124	2,136	2,279	2,187	1,923	1,964	1,942	1,957	1,978	2,024	1,995	1,938	1,878	1,950	1,877	1,802	1,826	1,805	1,758	1,752	1,757
Current Assets	-1.1%	1,469	1,486	1,465	1,397	1,110	1,130	1,054	1,046	1,015	1,062	1,053	1,038	1,006	1,111	1,025	947	913	962	998	995	963
Cash Equivalents	-8.0%	421	457	648	666	321	292	264	255	283	338	310	258	205	273	241	189	176	204	261	196	225
Inventory	6.4%	198	186	192	189	185	181	166	156	155	150	139	136	134	126	123	116	109	102	101	95.00	93.00
Net PPE	-1.0%	225	227	328	324	321	223	326	337	337	341	341	344	346	350	355	362	363	362	341	326	320
Goodwill	0%	83.00	83.00	93.00	93.00	93.00	83.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00
Liabilities	-6.9%	869	934	924	907	917	920	899	875	902	912	899	840	827	883	792	740	763	720	690	661	654
Current Liabilities	-11.8%	459	520	503	487	493	498	470	439	462	471	453	383	366	438	378	321	340	391	370	334	328
Long Term Debt	-0.2%	287	288	288	289	290	290	291	292	292	293	293	294	295	272	273	273	274	274	275	275	276
LT Debt, Current	0%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
LT Debt, Non Current	-100.0%	-	288	288	289	290	290	291	292	292	293	293	294	295	272	273	273	274	274	275	275	276
Shareholder's Equity	4.3%	1,255	1,203	1,356	1,280	1,006	1,044	1,043	1,082	1,075	1,113	1,096	1,098	1,051	1,067	1,084	1,062	1,063	1,085	1,068	1,091	1,102
Retained Earnings	2.7%	-1,306	-1,343	-1,456	-1,504	-1,741	-1,699	-1,671	-1,607	-1,576	-1,541	-1,541	-1,512	-1,515	-1,492	-1,450	-1,450	-1,420	-1,381	-1,376	-1,323	-1,281
Additional Paid-In Capital	1.6%	2,781	2,737	3,003	2,976	2,939	2,913	2,886	2,858	2,819	2,798	2,779	2,749	2,703	2,686	2,660	2,636	2,609	2,586	2,563	2,533	2,503
Shares Outstanding	1.3%	169	167	167	166	166	164	164	164	162	161	161	160	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	4,792	-	-	-	4,838	-	-	-	3,918	-	-	-	3,058	-	-	-	3,508	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-80.3%	21,108	107,237	99,708	215,710	-21,302	1,047	625	-2,306	21,678	31,021	82,777	33,063	-45,146	67,343	60,203	-4,432	-40,272	42,070	30,972	-23,177	22,212
Share Based Compensation	26.7%	32,755	25,843	23,915	28,504	22,643	26,483	26,051	23,377	18,343	19,019	25,600	27,552	15,451	24,885	22,620	22,846	19,813	21,387	26,729	28,245	24,616
Cashflow From Investing	-90.4%	-39,951	-20,982	-119,359	120,848	72,850	27,740	8,898	-40,538	-60,641	-742	-31,707	3,977	-37,732	-35,097	-8,227	14,351	17,492	-101,471	31,594	-7,253	-64,703
Cashflow From Financing	93.5%	-17,873	-276,497	1,567	7,836	-22,620	-271	-212	14,933	-16,024	-3,179	1,033	16,273	14,945	-151	-112	3,016	-4,924	1,746	2,906	1,150	963

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALKS Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
REVENUES:
Total revenues	$ 350,372	$ 287,595
EXPENSES:
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)	58,644	58,164
Research and development	67,611	63,770
Selling, general and administrative	179,749	167,833
Amortization of acquired intangible assets	1,059	8,800
Total expenses	307,063	298,567
OPERATING INCOME (LOSS) FROM CONTINUING OPERATIONS	43,309	(10,972)
OTHER INCOME (EXPENSE), NET:
Interest income	9,399	4,966
Interest expense	(5,978)	(5,288)
Other income (expense), net	182	(39)
Total other income (expense), net	3,603	(361)
INCOME (LOSS) BEFORE INCOME TAXES	46,912	(11,333)
INCOME TAX PROVISION	7,964	717
NET INCOME (LOSS) FROM CONTINUING OPERATIONS	38,948	(12,050)
DISCONTINUED OPERATIONS, NET OF TAX	(2,120)	(29,795)
NET INCOME (LOSS)	$ 36,828	$ (41,845)
EARNINGS (LOSS) PER ORDINARY SHARE:
Earnings (loss) per share from continuing operations - basic	$ 0.23	$ (0.07)
Loss per share from discontinued operations - basic	(0.01)	(0.18)
Earnings (loss) per share - basic	0.22	(0.25)
Earnings (loss) per share from continuing operations - diluted	0.23	(0.07)
Loss per share from discontinued operations - diluted	(0.01)	(0.18)
Earnings (loss) per share - diluted	$ 0.21	$ (0.25)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:
Basic	167,984	165,085
Diluted	172,981	165,085
COMPREHENSIVE INCOME (LOSS):
Net income (loss)	$ 36,828	$ (41,845)
Holding (loss) gain, net of a tax (benefit) provision of $(75) and $488, respectively	(491)	2,760
COMPREHENSIVE INCOME (LOSS)	36,337	(39,085)
Product sales, net
REVENUES:
Total revenues	233,536	214,727
Manufacturing and royalty revenues
REVENUES:
Total revenues	116,833	72,862
Research and development revenue
REVENUES:
Total revenues	$ 3	$ 6

ALKS Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 420,753	$ 457,469
Receivables, net	315,848	332,477
Investments—short-term	324,295	316,022
Inventory	198,369	186,406
Contract assets	1,229	706
Prepaid expenses and other current assets	111,539	98,166
Assets held for sale	96,792	94,260
Total current assets	1,468,825	1,485,506
PROPERTY, PLANT AND EQUIPMENT, NET	224,590	226,943
RIGHT-OF-USE ASSETS	89,683	91,460
INVESTMENTS—LONG-TERM	62,782	39,887
GOODWILL	83,027	83,027
INTANGIBLE ASSETS, NET	932	1,991
DEFERRED TAX ASSETS	182,536	195,888
OTHER ASSETS	11,521	11,521
TOTAL ASSETS	2,123,896	2,136,223
CURRENT LIABILITIES:
Accounts payable and accrued expenses	205,854	240,561
Accrued sales discounts, allowances and reserves	240,877	263,641
Operating lease liabilities—short-term	5,910	5,746
Contract liabilities—short-term	3,336	2,730
Current portion of long-term debt	3,000	3,000
Liabilities related to discontinued operations		4,542
Total current liabilities	458,977	520,220
LONG-TERM DEBT	287,095	287,730
OPERATING LEASE LIABILITIES—LONG-TERM	74,102	75,709
OTHER LONG-TERM LIABILITIES	48,959	49,878
Total liabilities	869,133	933,537
COMMITMENTS AND CONTINGENT LIABILITIES (Note 16)
SHAREHOLDERS’ EQUITY:
Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at March 31, 2024 and December 31, 2023
Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 175,734,220 and 172,569,051 shares issued; 169,184,516 and 166,979,833 shares outstanding at March 31, 2024 and December 31, 2023, respectively	1,757	1,726
Treasury shares, at cost (6,549,704 and 5,589,218 shares at March 31, 2024 and December 31, 2023, respectively)	(217,685)	(189,336)
Additional paid-in capital	2,780,992	2,736,934
Accumulated other comprehensive loss	(3,601)	(3,110)
Accumulated deficit	(1,306,700)	(1,343,528)
Total shareholders’ equity	1,254,763	1,202,686
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 2,123,896	$ 2,136,223

About Alkermes PLC

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

CEO	Mr. Richard F. Pops
WEBSITE	alkermes.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	2280

Alkermes PLC Frequently Asked Questions

What is the ticker symbol for Alkermes PLC? What does ALKS stand for in stocks?

ALKS is the stock ticker symbol of Alkermes PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alkermes PLC (ALKS)?

As of Fri May 03 2024, market cap of Alkermes PLC is 4.07 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALKS stock?

You can check ALKS's fair value in chart for subscribers.

What is the fair value of ALKS stock?

You can check ALKS's fair value in chart for subscribers. The fair value of Alkermes PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alkermes PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALKS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alkermes PLC a good stock to buy?

The fair value guage provides a quick view whether ALKS is over valued or under valued. Whether Alkermes PLC is cheap or expensive depends on the assumptions which impact Alkermes PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALKS.

What is Alkermes PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, ALKS's PE ratio (Price to Earnings) is 9.38 and Price to Sales (PS) ratio is 2.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALKS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alkermes PLC's stock?

In the past 10 years, Alkermes PLC has provided -0.064 (multiply by 100 for percentage) rate of return.